First Pharmaceutical Holdings (688197.SH): The transfer price in this inquiry is 42.19 yuan/share

Gelonghui, May 20, 丨 First Pharmaceutical Holdings (688197.SH) announced that based on the inquiry and subscription situation on May 20, 2024, the initial confirmed transfer price for this inquiry was 42.19 yuan/share.

Gelonghui FinanceMay 20 06:23 ET

First Pharmaceutical Holdings (688197.SH): Shareholders plan to transfer 1.61% of shares in an inquiry

Gelonghui, May 17 | Shouyao Holdings (688197.SH) announced that the shareholder to participate in the company's pre-launch shareholder inquiry and transfer is Beijing Yizhuang International Investment and Development Co., Ltd.; the total number of shares to be transferred by the transferor is 2,400,000 shares, accounting for 1.61% of the total share capital of Shouyao Holdings; this inquiry transfer is a private transfer and will not be carried out through centralized bidding transactions. The transferee transfers the transferred shares through an inquiry, and cannot be transferred within 6 months after the transfer.

Gelonghui FinanceMay 17 05:10 ET

First Pharmaceutical Holdings (688197.SH) announced 2023 annual results with a net loss of 186 million yuan

First Pharmaceutical Holdings (688197.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 5...

Zhitong FinanceApr 28 03:57 ET

First Pharmaceutical Holdings (688197.SH): 1.487,200 restricted shares banned on March 25

On March 15, Gelonghui Holdings (688197.SH) announced that the total number of shares in circulation in the company's current stock listing was 1.487,200 shares. The stock listing and circulation date is March 25, 2024.

Gelonghui FinanceMar 15 07:03 ET

First Pharmaceutical Holdings (688197.SH): The core self-developed products are all in the R&D stage, and no products have yet been launched to contribute to sales revenue

On March 14, Gelonghui Holdings (688197.SH) announced an announcement of abnormal fluctuations in stock trading. The company's daily operations are all normal, and every effort is being made to promote clinical research on the core pipeline. As of the disclosure date of this announcement, the core self-developed product SY-707 is undergoing pre-NDA communication based on the results of the registered clinical phase III trial; the NSCLC critical phase II trial of the third-generation ALK inhibitor SY-3505 against treatment failure with second-generation ALK inhibitors is undergoing rapid enrollment, comparing critical phase III clinical studies with crizotinib for first-line treatment of ALK-positive NSCLC patients

Gelonghui FinanceMar 14 06:26 ET

First Pharmaceutical Holdings (688197.SH) Performance Report: Net loss of 184 million yuan in 2023

Gelonghui, January 30丨First Pharmaceutical Holdings (688197.SH) announced its 2023 annual results report. During the reporting period, the company achieved total operating income of 5,2292 million yuan, an increase of 186.19% year on year; R&D expenses of 201.206 million yuan, up 0.89% year on year; net profit attributable to owners of the parent company - 18.38443 million yuan, a year-on-year increase of 10.275 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 197.22.5 million yuan.

Gelonghui FinanceJan 30 06:24 ET